Sentences with phrase «targeting myeloid»
Researchers at The University of Texas MD Anderson Cancer Center developed a novel chimeric mouse model to test the combination therapy using immune checkpoint blockades with therapies targeting myeloid - derived suppressor cells (MDSCs).
https://www.sciencedaily.com/ Not exact matches
Targeting exhausted immune cells may change the prognosis for patients with acute myeloid leukemia (AML) relapse after a stem cell transplant, according to Penn State College of Medicine researchers.
Take ponatinib, a drug that targets the hallmark molecular abnormality in chronic myeloid leukemia (CML).
For that, they quantified how 85 nanoparticles delivered DNA barcodes to eight cell populations in the spleen, and found that cell types derived from myeloid progenitors tended to be targeted by similar nanoparticles.
«New therapeutic target for treatment of acute myeloid leukemia discovered.»
A study by the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS) has found new interactions between two molecules involved in acute myeloid leukemia (AML), STAT3 and PRL - 3, which may offer a new therapeutic target for cancer treatment.
«Opening the door to the cause of myeloid leukemia: Finding the targets of common mutation.»
«Prostaglandin EI inhibits leukemia stem cells: Targeting leukemia stem cells in combination with standard chemotherapy may improve treatment for chronic myeloid leukemia.»
«Preclinical results support entinostat's role in targeting the tumor microenvironment: Entinostat inhibits function of myeloid derived suppressor cells resulting in enhanced antitumor effect in murine models of lung and renal cell carcinoma.»
Locafaro G *, Andolfi G *, Russo F, Camisa B, Ciceri F, Bondanza A, Roncarolo MG *, Gregori S. HLA class I - dependent targeting of myeloid leukemia by IL -10-engineered human CD4 + Tr1 cells.
Biernacki's research focuses on developing targeted immunotherapy for pediatric acute myeloid leukemia, or AML.
In addition to being integral to cell biology, tyrosine kinases also present targets for new anticancer therapies: One of the most highly touted, rationally designed anticancer compounds, Gleevec, inhibits an oncogenic tyrosine kinase whose aberrant activity fuels the rampant growth of cells in patients with chronic myeloid leukemia.
One such avenue, explored in partnership with oncologist Charles Sawyers, then at the University of California, Los Angeles, helped determine why some patients fail to improve despite short - term treatment with the cancer drug Gleevec, which targets a genetic mutation underlying chronic myeloid leukemia, a life - threatening blood cancer.
These mutant kinases are attractive therapeutic targets, as demonstrated by the efficacy of imatinib in BCR - ABL — positive chronic myelogenous leukemia (CML), 5 as well as in MPD associated with activating alleles involving PDGFRA or PDGFRB.2, 6,7 In addition, activating mutations in the FLT3 receptor tyrosine kinase are the most common genetic event in acute myeloid leukemia (AML), and specific inhibitors of the FMS - like tyrosine kinase 3 (FLT3) have entered late - stage clinical trials.8 Although mutations in tyrosine kinases and in other genes have been identified in a subset of MPD and AML, in many cases the genetic events that contribute to the molecular pathogenesis of these diseases remain unknown.
Protein profiling may identify moving treatments targets for acute myeloid leukemia.
The award will support her research targeting protein arginine methylation in MLL - fusion acute myeloid leukemia.
5) Saurabh K, Scherzer MT, Shah PP, Mims AS, Lockwood WW, Kraft AS, Beverly LJ (2014) The PIM family of oncoproteins: small kinases with huge implications in myeloid leukemogenesis and as therapeutic targets.
This represents an ideal drug target, said Vogelstein, and is exemplified by the success of the drug Gleevec in treating chronic myeloid leukemia.
20 - 30 % of patients with acute myeloid leukemia have mutations of the FLT3 biomarker that make them eligible for several FLT3 - targeted small molecule therapies currently in late stage clinical trials.
Together, these data define METTL3 as a regulator of a chromatin - based pathway that is necessary for maintenance of the leukaemic state and identify this enzyme as a potential therapeutic target for acute myeloid leukaemia.
In 2016, Dmitry I. Gabrilovich, M.D., Ph.D., program leader of Wistar's Translational Tumor Immunology program, and his research team identified a marker for myeloid - derived suppressor cells (MDSCs), a population of immune cells implicated in tumor resistance to various types of cancer treatment, including targeted therapies, chemotherapy and immunotherapy.
We performed targeted next - generation sequencing for 120 genes associated with myeloid neoplasms on megakaryocytes isolated from aspirated bone marrow.
, Kraft AS, Beverly LJ (2014) The PIM family of oncoproteins: small kinases with huge implications in myeloid leukemogenesis and as therapeutic targets.
Mar. 14, 2018 — New agreement will pursue therapies targeting MCL1 (myeloid cell leukemia 1), which is highly prevalent in many difficult - to - treat cancers.
Immunotherapeutic concepts to target acute myeloid leukemia: focusing on the role of monoclonal antibodies, hypomethylating agents and the leukemic microenvironment